Some of our favorite lightweight gaming options are comparable in performance to the best gaming laptops regardless of form factor. What you do typically sacrifice is thermal performance ...

Hims and Hers plans to stop selling compounded weight loss drugs after an FDA update. Hims and Hers' stock fell over 19% in after-hours trading on Monday. The FDA removed semaglutide injections ...

InvestingPro analysis suggests the stock is currently trading near its Fair Value, with analysts setting price targets ranging from $125 to $166. Despite some modest price recovery in PE and PVC ...

Hims stock stood about 22% lower in recent trading. Novo Nordisk shares jumped as much as 4% in Denmark. Hims will stop offering mass compounding of semaglutide after the first quarter ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss treatments. Metsera shares are going for $30 at writing versus their IPO ...

The U.S. stock market was mostly up early afternoon Monday, with the equal-weight version of the S&P 500 staging a partial recovery from Friday’s slump. The Invesco S&P 500 Equal Weight ETF ...

Novo Nordisk stock is up around 75% despite a pullback in recent months. There's no secret to their success: Both companies have blockbuster weight-loss drugs. But the obesity market could soon ...

Analyst upgrades can temporarily boost a stock's price; opportunity for short gains. Downgrades often cause immediate selling and lower stock prices; buying chance for others. Long-term investors ...

It's impossible to predict market corrections; historically, they're a normal stock market behavior. Distinguishing between a market correction and a crash or bear market isn't clear until it's over.